Involvement of MR signaling in obesity-associated cardiovascular morbidity and mortality is supported by both clinical and preclinical work, from us [4, 6, 7, 13, 21] and others [19, 33, 53], utilizing MR antagonists. This evidence concerns the gene NR3C2 and Obesity.